• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从维生素K拮抗剂转换为直接口服抗凝剂的真实生活患者的满意度、生活质量和治疗依从性评估

Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants.

作者信息

Serrao Alessandra, Lucani Benedetta, Assanto Manfredi Giovanni, Fiori Luciano, Baldacci Erminia, Aprile Simona Michela, Chistolini Antonio

机构信息

"Sapienza", University of Rome, Via Benevento 6, 00161, Rome, Italy.

出版信息

J Thromb Thrombolysis. 2020 Oct;50(3):718-723. doi: 10.1007/s11239-020-02070-2.

DOI:10.1007/s11239-020-02070-2
PMID:32112201
Abstract

Anticoagulant therapy has undergone a significant change since direct oral anticoagulants (DOACs) introduction. Their obvious advantages including the fixed dose, the few interactions and less frequent controls, have made them the first choice anticoagulant therapy. More and more patients have therefore switched from therapy with vitamin K antagonists (VKAs) to DOACs. Aim of our study was to assess the satisfaction, quality of life (QoL) and therapy adherence of patients who switched from VKA to DOACs therapy. This single center study evaluated satisfaction and QoL of 107 patients who switched from VKA to DOACs therapy through Anti-Clot Treatment Scale and SF-36 respectively. The questionnaires were administered before therapy change, after 3 months of DOACs therapy and then annually. We also evaluated DOACs therapy adherence with a questionnaire administered each visit and through the measures of DOACs plasma levels. Patients' satisfaction and QoL were high during VKA therapy, but with DOACs we observed an improvement after the first 3 months and then maintained over the time of DOACs therapy. DOACs adherence was excellent, also confirmed by DOACs plasma levels.

摘要

自直接口服抗凝剂(DOACs)问世以来,抗凝治疗发生了重大变化。它们具有明显的优势,包括固定剂量、相互作用少且监测频率低,这使其成为抗凝治疗的首选。因此,越来越多的患者从维生素K拮抗剂(VKA)治疗转向DOACs治疗。我们研究的目的是评估从VKA转换为DOACs治疗的患者的满意度、生活质量(QoL)和治疗依从性。这项单中心研究分别通过抗凝治疗量表和SF-36评估了107例从VKA转换为DOACs治疗的患者的满意度和生活质量。问卷在治疗转换前、DOACs治疗3个月后以及之后每年进行一次。我们还通过每次就诊时发放的问卷以及DOACs血浆水平测量来评估DOACs治疗的依从性。在VKA治疗期间患者的满意度和生活质量较高,但在DOACs治疗中,我们观察到在最初3个月后有所改善,并且在DOACs治疗期间一直保持。DOACs的依从性很好,DOACs血浆水平也证实了这一点。

相似文献

1
Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants.从维生素K拮抗剂转换为直接口服抗凝剂的真实生活患者的满意度、生活质量和治疗依从性评估
J Thromb Thrombolysis. 2020 Oct;50(3):718-723. doi: 10.1007/s11239-020-02070-2.
2
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.在 1 年随访期间,接受稳定维生素 K 拮抗剂治疗或换用非维生素 K 拮抗剂口服抗凝剂的心房颤动患者的生活质量和患者满意度:AF 登记处的 PREFER 子研究。
Arch Cardiovasc Dis. 2018 Feb;111(2):74-84. doi: 10.1016/j.acvd.2017.04.007. Epub 2017 Sep 21.
3
Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.接受维生素K拮抗剂或直接口服抗凝剂治疗的非瓣膜性心房颤动患者:患者概况及长期随访结果
Arch Cardiol Mex. 2019;89(4):382-392. doi: 10.24875/ACM.19000023.
4
Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation.非瓣膜性心房颤动患者中,与直接口服抗凝剂相比,患者对维生素K拮抗剂的负担和益处的满意度、生活质量及认知情况。
J Comp Eff Res. 2017 Jun;6(4):303-312. doi: 10.2217/cer-2016-0078. Epub 2017 Mar 29.
5
Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.直接口服抗凝剂与维生素 K 拮抗剂在合并生物瓣心脏瓣膜的心房颤动患者中的临床获益比较。
Clin Ther. 2019 Dec;41(12):2549-2557. doi: 10.1016/j.clinthera.2019.10.008. Epub 2019 Nov 14.
6
Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.静脉血栓栓塞症抗凝延长治疗患者换用直接口服抗凝剂后对患者满意度的影响:SWAN 研究。
PLoS One. 2020 Jun 4;15(6):e0234048. doi: 10.1371/journal.pone.0234048. eCollection 2020.
7
[Quality of life of elderly people on oral anticoagulant for atrial fibrillation: VKA versus direct oral anticoagulants].[口服抗凝剂治疗心房颤动的老年人的生活质量:维生素K拮抗剂与直接口服抗凝剂的比较]
Geriatr Psychol Neuropsychiatr Vieil. 2015 Mar;13(1):45-54. doi: 10.1684/pnv.2015.0516.
8
Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.维生素K拮抗剂或直接口服抗凝剂在实际应用中的大出血情况
Int J Cardiol. 2017 Jan 15;227:261-266. doi: 10.1016/j.ijcard.2016.11.117. Epub 2016 Nov 9.
9
The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation.口服抗凝剂与非瓣膜性心房颤动患者癌症发病率的相关性。
Thromb Haemost. 2020 Oct;120(10):1384-1394. doi: 10.1055/s-0040-1714213. Epub 2020 Jul 27.
10
The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in nonvalvular atrial fibrillation patients already on vitamin K antagonist.意大利血栓形成中心联合会关于直接口服抗凝剂(DOACs)的标准:在已服用维生素K拮抗剂的非瓣膜性心房颤动患者中的“真实世界”应用。
Intern Emerg Med. 2015 Mar;10(2):157-63. doi: 10.1007/s11739-014-1155-7. Epub 2014 Dec 9.

本文引用的文献

1
Differences between patient-driven adherence to vitamin K antagonists and direct oral anticoagulants. Do few missed doses matter? ACO-MEMS Study.患者对维生素 K 拮抗剂和直接口服抗凝剂的依从性差异。漏服几次真的那么重要吗?ACO-MEMS 研究。
Thromb Res. 2019 Jul;179:20-27. doi: 10.1016/j.thromres.2019.04.023. Epub 2019 Apr 24.
2
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.心房颤动急性冠状动脉综合征或经皮冠状动脉介入治疗后的抗血栓治疗。
N Engl J Med. 2019 Apr 18;380(16):1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17.
3
Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation - a network meta-analysis of real-world data.
直接作用口服抗凝剂与维生素K拮抗剂在非瓣膜性心房颤动中的安全性和有效性——基于真实世界数据的网状荟萃分析
Vasa. 2019 Mar;48(2):134-147. doi: 10.1024/0301-1526/a000746. Epub 2018 Nov 5.
4
NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands.在新患者中,新型口服抗凝药(NOACs)取代维生素K拮抗剂(VKA)成为首选口服抗凝剂:一项在荷兰560家药店开展的药物利用研究。
Thromb J. 2018 Apr 18;16:7. doi: 10.1186/s12959-017-0156-y. eCollection 2018.
5
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.房颤患者 PCI 术后的达比加群双重抗血栓治疗。
N Engl J Med. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27.
6
Changes in Use of Anticoagulation in Patients With Atrial Fibrillation Within a Primary Care Network Associated With the Introduction of Direct Oral Anticoagulants.与直接口服抗凝剂引入相关的基层医疗网络中房颤患者抗凝治疗使用情况的变化
Am J Cardiol. 2017 Sep 1;120(5):786-791. doi: 10.1016/j.amjcard.2017.05.055. Epub 2017 Jun 15.
7
Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance.通过治疗依从性评估利伐沙班治疗非瓣膜性心房颤动患者的生活质量
Qual Life Res. 2017 Mar;26(3):647-654. doi: 10.1007/s11136-016-1489-x. Epub 2017 Jan 6.
8
Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study.患者报告的利伐沙班用于预防心房颤动中风的治疗满意度。一项法国观察性研究,即SAFARI研究。
PLoS One. 2016 Dec 9;11(12):e0166218. doi: 10.1371/journal.pone.0166218. eCollection 2016.
9
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.直接口服抗凝剂抗凝活性的实验室评估:一项系统评价
Chest. 2017 Jan;151(1):127-138. doi: 10.1016/j.chest.2016.08.1462. Epub 2016 Sep 13.
10
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.接受经皮冠状动脉介入治疗患者使用双联抗血小板治疗及其预后:ROCKET AF试验
JACC Cardiovasc Interv. 2016 Aug 22;9(16):1694-702. doi: 10.1016/j.jcin.2016.05.039.